Barclays set a €70.00 ($81.40) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the stock.

Several other analysts have also issued reports on the company. Morgan Stanley set a €77.00 ($89.53) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Monday, September 3rd. Jefferies Financial Group set a €59.00 ($68.60) target price on Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Monday, October 1st. UBS Group set a €57.00 ($66.28) target price on Fresenius SE & Co KGaA and gave the stock a sell rating in a report on Monday, September 17th. Warburg Research set a €80.00 ($93.02) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Friday, September 28th. Finally, Commerzbank set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. Fresenius SE & Co KGaA presently has a consensus rating of Buy and an average price target of €74.20 ($86.28).

FRE opened at €52.82 ($61.42) on Wednesday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: The Discount Rate – What You Need to Know

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.